Nanjing Vishee Medical Technology Stock Forecast for 2022 - 2025 - 2030

Updated on 12/09/2022

Stock Rating
12
Price Target
¥75.23
Consensus
Outperform
Upside
0.00%
Analysts
0
Stock Rating
12
Upside
0.00%
Analysts
0
Price Target
¥75.23

Nanjing Vishee Medical Technology Stock Forecast and Price Target

The average target price for Nanjing Vishee Medical Technology's stock set by renowned analysts in recent months is ¥75.23, representing a potential upside of approximately 100% from its last closing price if met by 2023. This estimation is based on a high estimate of ¥82.46 and a low estimate of ¥68.00.

¥75.23

0.00% Upside

Buy
Buy

Nanjing Vishee Medical Technology Fair Value Forecast for 2022 - 2025 - 2030

Nanjing Vishee Medical Technology's Price has decreased by 0.00% In the last year, from ¥33.00 to ¥33.00. In the following year, the 0 analysts surveyed believe that Nanjing Vishee Medical Technology's Fair Value will decrease by 0.00%, reaching ¥33.00. According to professionals, by 2030, Nanjing Vishee Medical Technology's Fair Value will have decreased by 0.00%, falling down to ¥33.00.

2022 Fair Value Forecast
¥33.00
2023 Fair Value Forecast
¥33.00
2024 Fair Value Forecast
¥33.00
2025 Fair Value Forecast
¥33.00
2026 Fair Value Forecast
¥33.00
2027 Fair Value Forecast
¥33.00
2028 Fair Value Forecast
¥33.00
2029 Fair Value Forecast
¥33.00
2030 Fair Value Forecast
¥33.00

Nanjing Vishee Medical Technology Revenue Forecast for 2022 - 2025 - 2030

In the last year, Nanjing Vishee Medical Technology's Revenue has grown by 13.66%, from ¥378.37M to ¥430.04M. In the following year, the 0 analysts surveyed believe that Nanjing Vishee Medical Technology's Revenue will decrease by 12.02%, reaching ¥378.35M. According to professionals, by 2030, Nanjing Vishee Medical Technology's Revenue will have decreased by 7.30%, falling down to ¥398.65M.

2022 Rev Forecast
¥0.38B
2023 Rev Forecast
¥0.40B
2024 Rev Forecast
¥0.39B
2025 Rev Forecast
¥0.41B
2026 Rev Forecast
¥0.40B
2027 Rev Forecast
¥0.40B
2028 Rev Forecast
¥0.40B
2029 Rev Forecast
¥0.40B
2030 Rev Forecast
¥0.40B

Nanjing Vishee Medical Technology Dividend per Share Forecast for 2022 - 2025 - 2030

Nanjing Vishee Medical Technology Free Cash Flow Forecast for 2022 - 2025 - 2030

In the last year, Nanjing Vishee Medical Technology's Free Cash Flow has decreased by 35.82%, from ¥109.11M to ¥70.03M. For next year, analysts predict Free Cash Flow of ¥109.11M, which would mean an increase of 55.80%. Over the next nine years, experts predict that Nanjing Vishee Medical Technology's Free Cash Flow will grow at a rate of 46.94%.

2022 FCF Forecast
¥0.11B
2023 FCF Forecast
¥0.10B
2024 FCF Forecast
¥0.11B
2025 FCF Forecast
¥0.10B
2026 FCF Forecast
¥0.10B
2027 FCF Forecast
¥0.10B
2028 FCF Forecast
¥0.11B
2029 FCF Forecast
¥0.10B
2030 FCF Forecast
¥0.10B

Nanjing Vishee Medical Technology Net Income Forecast for 2022 - 2025 - 2030

In the last year, Nanjing Vishee Medical Technology's Net Income has grown by 23.77%, rising from ¥143.66M to ¥177.81M. According to the 0 analysts polled, in the next year, Nanjing Vishee Medical Technology's Net Income will fall by 19.21%, reaching ¥143.65M. By 2030, professionals believe that Nanjing Vishee Medical Technology's Net Income will have decreased by 11.02%, falling to ¥158.22M.

2022 NI Forecast
¥0.14B
2023 NI Forecast
¥0.16B
2024 NI Forecast
¥0.16B
2025 NI Forecast
¥0.16B
2026 NI Forecast
¥0.16B
2027 NI Forecast
¥0.16B
2028 NI Forecast
¥0.16B
2029 NI Forecast
¥0.16B
2030 NI Forecast
¥0.16B

Nanjing Vishee Medical Technology EBITDA Forecast for 2022 - 2025 - 2030

In the last year, Nanjing Vishee Medical Technology's EBITDA has grown, rising from ¥150.33M to ¥168.33M – a growth of 11.97%. According to 0 prominent analysts, Nanjing Vishee Medical Technology's EBITDA will fall by 10.69% in the next year, reaching ¥150.34M. By 2030, professionals believe that Nanjing Vishee Medical Technology's EBITDA will decrease by 6.56%, reaching ¥157.29M – a concerning trend for the company.

2022 EBITDA Forecast
¥0.15B
2023 EBITDA Forecast
¥0.16B
2024 EBITDA Forecast
¥0.16B
2025 EBITDA Forecast
¥0.16B
2026 EBITDA Forecast
¥0.16B
2027 EBITDA Forecast
¥0.16B
2028 EBITDA Forecast
¥0.16B
2029 EBITDA Forecast
¥0.16B
2030 EBITDA Forecast
¥0.16B

Nanjing Vishee Medical Technology EBIT Forecast for 2022 - 2025 - 2030

Nanjing Vishee Medical Technology's EBIT has grown In the last year, rising from ¥141.90M to ¥158.44M – a growth of 11.66%. In the following year, 0 experts forecast Nanjing Vishee Medical Technology's EBIT will decrease by 10.44%, to ¥141.90M. In 2030, professionals predict that Nanjing Vishee Medical Technology's EBIT will decrease by 6.41%, to ¥148.29M.

2022 EBIT Forecast
¥0.14B
2023 EBIT Forecast
¥0.15B
2024 EBIT Forecast
¥0.15B
2025 EBIT Forecast
¥0.15B
2026 EBIT Forecast
¥0.15B
2027 EBIT Forecast
¥0.15B
2028 EBIT Forecast
¥0.15B
2029 EBIT Forecast
¥0.15B
2030 EBIT Forecast
¥0.15B

Nanjing Vishee Medical Technology EPS Price Prediction Forecast for 2022 - 2025 - 2030

Nanjing Vishee Medical Technology's EPS has decreased by 0.00% In the last year, from ¥2.20 to ¥2.20. In the following year, the 0 analysts surveyed believe that Nanjing Vishee Medical Technology's EPS will decrease by 0.00%, reaching ¥2.20. According to professionals, by 2030, Nanjing Vishee Medical Technology's EPS will have decreased by 0.00%, falling down to ¥2.20.

2022 EPS Forecast
¥2.20
2023 EPS Forecast
¥2.20
2024 EPS Forecast
¥2.20
2025 EPS Forecast
¥2.20
2026 EPS Forecast
¥2.20
2027 EPS Forecast
¥2.20
2028 EPS Forecast
¥2.20
2029 EPS Forecast
¥2.20
2030 EPS Forecast
¥2.20